Ibrutinib, a novel agent in relapsed or refractory chronic lymphocytic leukemia.
作者信息
Ivanescu Ana-Maria, Oprea Madalina, Turbatu Andrei, Colita Andrei, Lupu Anca Roxana
机构信息
Department of Hematology, Coltea Clinical Hospital, Bucharest, Romania.
出版信息
Maedica (Bucur). 2014 Jun;9(2):217-8.
Abstract
摘要
相似文献
1
Ibrutinib, a novel agent in relapsed or refractory chronic lymphocytic leukemia.伊布替尼，一种用于复发或难治性慢性淋巴细胞白血病的新型药物。
Maedica (Bucur). 2014 Jun;9(2):217-8.
2
Treatment Outcomes of Novel Targeted Agents in Relapse/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-Analysis.新型靶向药物治疗复发/难治性慢性淋巴细胞白血病的疗效：一项系统评价和网状Meta分析
J Clin Med. 2019 May 23;8(5):737. doi: 10.3390/jcm8050737.
3
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.在 III 期 RESONATE 研究中，伊布替尼对比奥法木单抗治疗先前治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者的血液学和免疫学功能参数及患者生存状况的改善。
Clin Lymphoma Myeloma Leuk. 2018 Dec;18(12):803-813.e7. doi: 10.1016/j.clml.2018.08.007. Epub 2018 Aug 18.
4
The emerging role of ibrutinib in the treatment of chronic lymphocytic leukemia.伊布替尼在慢性淋巴细胞白血病治疗中的新作用。
Expert Rev Hematol. 2013 Oct;6(5):543-6. doi: 10.1586/17474086.2013.831324. Epub 2013 Oct 2.
5
Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.依鲁替尼治疗慢性淋巴细胞白血病的药代动力学和药效学评估：低剂量的理论依据。
Expert Opin Drug Metab Toxicol. 2016 Nov;12(11):1381-1392. doi: 10.1080/17425255.2016.1239717. Epub 2016 Oct 11.
6
A Novel Case of Penile Gangrene in a Patient Treated with Ibrutinib for Chronic Lymphocytic Leukemia.一例接受伊布替尼治疗慢性淋巴细胞白血病患者发生阴茎坏疽的罕见病例。
Case Rep Oncol Med. 2016;2016:6980198. doi: 10.1155/2016/6980198. Epub 2016 Nov 23.
7
"Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia".EB病毒重新激活及伊布替尼治疗复发/难治性慢性淋巴细胞白血病后发生的噬血细胞性淋巴组织细胞增生症
Leuk Res Rep. 2017 Jan 22;7:11-13. doi: 10.1016/j.lrr.2017.01.002. eCollection 2017.
8
Ibrutinib-induced severe liver injury.依鲁替尼诱发的严重肝损伤。
Clin Case Rep. 2017 Mar 15;5(6):735-738. doi: 10.1002/ccr3.881. eCollection 2017 Jun.
9
What Is the Role of Chemotherapy in Patients With Chronic Lymphocytic Leukemia?化疗在慢性淋巴细胞白血病患者中起什么作用？
Clin Lymphoma Myeloma Leuk. 2017 Nov;17(11):723-727. doi: 10.1016/j.clml.2017.06.023. Epub 2017 Jul 12.
10
[Small Molecules in the Treatment of Chronic Lymphocytic Leukemia in 2015 and in the Near Future].[2015年及不久的将来用于治疗慢性淋巴细胞白血病的小分子药物]
Klin Onkol. 2015;28 Suppl 3:3S45-9. doi: 10.14735/amko20153s45.
引用本文的文献
1
Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy.患者来源肿瘤细胞的药物基因组学全景分析为精准肿瘤治疗提供信息。
Nat Genet. 2018 Oct;50(10):1399-1411. doi: 10.1038/s41588-018-0209-6. Epub 2018 Sep 27.
本文引用的文献
1
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.伊布替尼作为初治老年慢性淋巴细胞白血病或小淋巴细胞淋巴瘤患者的治疗方案：一项开放标签、多中心、1b/2 期临床试验。
Lancet Oncol. 2014 Jan;15(1):48-58. doi: 10.1016/S1470-2045(13)70513-8. Epub 2013 Dec 10.
2
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.BTK 抑制可通过其对 B 细胞受体信号活性的影响来靶向体内 CLL 增殖。
Leukemia. 2014 Mar;28(3):649-57. doi: 10.1038/leu.2013.358. Epub 2013 Nov 25.
3
Novel agents for chronic lymphocytic leukemia.新型慢性淋巴细胞白血病药物。
J Hematol Oncol. 2013 May 16;6:36. doi: 10.1186/1756-8722-6-36.
Zotero 插件